A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

NCT04014205 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Part 1：r/r B-cell Malignancies
Part 2：B-cell Malignancies

Interventions

DRUG: Orelabrutinib (ICP-022)

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.